Physician profile
Mitchell Robert Goldstein
NPI 1659335636
$5,709.89
in general payments reported to CMS, 2019-2025
28 companies · $1,640 in 2025
The $1,640 reported for 2025 was more than what 92% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $200 · 2021: $240 · 2022: $518 · 2023: $748 · 2024: $1,194 · 2025: $1,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,555 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,554.86 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,006.02 | 2021-2025 | |
| Alkermes, INC. | $966.41 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $577.30 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $489.07 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Corium, LLC | $354.06 | 2021-2025 | Azstarys |
| Lundbeck LLC | $336.98 | 2019-2025 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $274.00 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $270.12 | 2019-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $269.57 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $249.94 | 2019-2025 | Ingrezza |
| Allergan, INC. | $217.28 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.34 | 2019-2020 | |
| Shire North American Group INC | $86.32 | 2019 | |
| Supernus Pharmaceuticals, INC. | $77.74 | 2023-2024 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $69.74 | 2024-2025 | Auvelity |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $66.13 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $61.47 | 2019-2025 | Fanapt |
| Tris Pharma INC | $41.22 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $38.92 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $26.47 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $24.07 | 2025 | Jornay Pm |
| Noven Therapeutics, LLC | $20.80 | 2023 | Secuado |
| Almatica Pharma LLC | $16.30 | 2024 | Loreev Xr |
| Rhodes Pharmaceuticals L.P. | $14.78 | 2019 | |
| Bioxcel Therapeutics, INC. | $13.66 | 2023 | Igalmi |
| Avanir Pharmaceuticals, INC. | $12.59 | 2019 | |
| Bausch Health US, LLC | $12.59 | 2020 | |
| Adlon Therapeutics L.P. | $12.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.